Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
Avidity Biosciences (Nasdaq: RNA) has appointed John B. Moriarty, Jr., J.D. as Chief Legal Officer and Corporate Secretary, effective immediately. With nearly 30 years of industry experience, Moriarty brings extensive legal expertise to guide the company through transformational growth. He succeeds John W. Wallen III, Ph.D., J.D., who will remain with the company through year-end and transition as a consultant.
Moriarty's previous roles include Executive VP and Chief Legal Officer at Mirati Therapeutics, Chief Legal Officer at Olema Oncology, and General Counsel positions at Portola Pharmaceuticals, Alexion, and Elan His appointment comes as Avidity advances three clinical development programs for rare muscle diseases and expands its AOC platform pipeline.
Avidity Biosciences (Nasdaq: RNA) ha nominato John B. Moriarty, Jr., J.D. come Chief Legal Officer e Corporate Secretary, con effetto immediato. Con quasi 30 anni di esperienza nel settore, Moriarty porta una vasta esperienza legale per guidare l'azienda attraverso una crescita trasformazionale. Succede a John W. Wallen III, Ph.D., J.D., che rimarrà con l'azienda fino alla fine dell'anno e passerà a un ruolo di consulente.
Le esperienze precedenti di Moriarty includono Executive VP e Chief Legal Officer presso Mirati Therapeutics, Chief Legal Officer presso Olema Oncology, e ruoli di General Counsel presso Portola Pharmaceuticals, Alexion ed Elan. La sua nomina arriva mentre Avidity avanza tre programmi di sviluppo clinico per malattie muscolari rare e amplia il proprio portafoglio della piattaforma AOC.
Avidity Biosciences (Nasdaq: RNA) ha nombrado a John B. Moriarty, Jr., J.D. como Director Legal y Secretario Corporativo, con efecto inmediato. Con casi 30 años de experiencia en la industria, Moriarty aporta una amplia experiencia legal para guiar a la empresa a través de un crecimiento transformacional. Sucede a John W. Wallen III, Ph.D., J.D., quien permanecerá en la empresa hasta fin de año y hará la transición como consultor.
Los roles anteriores de Moriarty incluyen Vicepresidente Ejecutivo y Director Legal en Mirati Therapeutics, Director Legal en Olema Oncology, y posiciones de Asesor Legal en Portola Pharmaceuticals, Alexion y Elan. Su nombramiento se produce mientras Avidity avanza tres programas de desarrollo clínico para enfermedades musculares raras y amplía su cartera de plataformas AOC.
Avidity Biosciences (Nasdaq: RNA)가 John B. Moriarty, Jr., J.D.를 법무 담당 최고 책임자 및 기업 비서로 즉각 임명했습니다. 산업 경력 30년을 자랑하는 Moriarty는 회사의 변혁적 성장을 이끌기 위한 폭넓은 법률 전문 지식을 제공합니다. 그는 John W. Wallen III, Ph.D., J.D.의 뒤를 이어 임명되었으며, Wallen은 연말까지 회사에 남아 컨설턴트로 전환할 예정입니다.
Moriarty의 이전 역할에는 Mirati Therapeutics의 법무 담당 부사장 및 최고 법무 책임자, Olema Oncology의 법무 책임자, Portola Pharmaceuticals, Alexion 및 Elan의 법률 고문 등이 포함됩니다. 그의 임명은 Avidity가 희귀 근육 질환을 위한 세 가지 임상 개발 프로그램을 진행하고 AOC 플랫폼 파이프라인을 확장하는 가운데 이루어졌습니다.
Avidity Biosciences (Nasdaq: RNA) a nommé John B. Moriarty, Jr., J.D. au poste de Directeur Juridique et Secrétaire Général, avec effet immédiat. Fort de près de 30 ans d'expérience dans l'industrie, Moriarty apporte une expertise juridique considérable pour guider l'entreprise dans une croissance transformative. Il succède à John W. Wallen III, Ph.D., J.D., qui restera avec l'entreprise jusqu'à la fin de l'année et passera à un rôle de consultant.
Avant cela, Moriarty a occupé les postes de Vice-Président Exécutif et Directeur Juridique chez Mirati Therapeutics, de Directeur Juridique chez Olema Oncology, et de Conseiller Juridique chez Portola Pharmaceuticals, Alexion et Elan. Sa nomination intervient alors qu'Avidity avance trois programmes de développement clinique pour des maladies musculaires rares et élargit son pipeline de plateforme AOC.
Avidity Biosciences (Nasdaq: RNA) hat John B. Moriarty, Jr., J.D. mit sofortiger Wirkung zum Chief Legal Officer und Corporate Secretary ernannt. Mit nahezu 30 Jahren Branchenerfahrung bringt Moriarty umfangreiche rechtliche Expertise mit, um das Unternehmen durch transformative Wachstumsphasen zu führen. Er tritt die Nachfolge von John W. Wallen III, Ph.D., J.D. an, der bis zum Jahresende im Unternehmen bleibt und als Berater wechselt.
Zuvor war Moriarty Executive VP und Chief Legal Officer bei Mirati Therapeutics, Chief Legal Officer bei Olema Oncology und hatte Positionen als General Counsel bei Portola Pharmaceuticals, Alexion und Elan inne. Seine Ernennung erfolgt zeitgleich mit der Weiterentwicklung von drei klinischen Entwicklungsprogrammen für seltene Muskelkrankheiten und der Erweiterung der AOC-Plattform-Pipeline von Avidity.
- Appointment of John B. Moriarty, Jr. as Chief Legal Officer, bringing 30 years of industry experience
- Advancement of three clinical development programs for rare muscle diseases
- Expansion of AOC platform pipeline
- Preparation for global commercial execution
- None.
Mr. Moriarty succeeds John W. Wallen III, Ph.D., J.D., who served as General Counsel since 2019 and has been head of intellectual property since Avidity's inception in 2014. Dr. Wallen will remain with the company through year-end and will transition as a consultant.
"We are pleased to have John join our leadership team. His extensive legal expertise and experience in leading biopharmaceutical companies through transformational growth will be instrumental as we continue to advance our three clinical development programs for the treatment of three distinct rare muscle diseases, expand our pipeline utilizing our broad AOC platform and build an integrated global organization," said Sarah Boyce, president and chief executive officer. "On behalf of our Avidity team, we extend our deepest gratitude to Dr. Wallen for his exceptional leadership and substantial contributions since our inception, including establishing a solid legal framework and securing our intellectual property for our AOC platform."
Mr. Moriarty was most recently the Executive Vice President, Chief Legal Officer and Corporate Secretary at Mirati Therapeutics where he led the global legal team, executed business transactions and enhanced corporate governance, which was acquired by Bristol Myers Squibb. Previously, he was the Chief Legal Officer at Olema Oncology, leading all legal, compliance, and governance functions during its evolution from a private startup to a public development-stage company. Prior to that, he was the Executive Vice President and General Counsel for Portola Pharmaceuticals, Inc., which was acquired by Alexion Pharmaceuticals, Inc. Prior to Portola, Mr. Moriarty was General Counsel of Alexion and was General Counsel and Chief Legal Officer at Elan Corporation plc. Mr. Moriarty earned a B.A. from the University of Virginia and a J.D. from the University of Georgia School of Law cum laude.
"I am excited to join Avidity at such a pivotal time in the company's transformation as it advances potential first-in-class and best-in-class therapies in development and prepares for global commercial execution," said Mr. Moriarty. "I look forward to collaborating with the executive leadership team as we realize our vision to profoundly improve people's lives by revolutionizing the delivery of RNA therapeutics."
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.
Forward-Looking Statements
Avidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the advancement of Avidity's clinical development programs; the expansion of Avidity's pipeline using its AOC platform; building an integrated global organization; the advancement of multiple first-in-class and best-in-class therapies by Avidity; and Avidity's preparation for global commercial execution.
The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business, including, without limitation: Avidity may not be able to resolve the partial clinical hold related to the serious adverse event which occurred in the Phase 1/2 MARINA® trial; additional data related to Avidity's current clinical programs that continues to become available may be inconsistent with the data produced as of the respective data cutoff dates; unexpected adverse side effects to, or inadequate efficacy of, Avidity's product candidates that may delay or limit their development, regulatory approval and/or commercialization; Avidity's approach to the discovery and development of product candidates based on its AOC platform is unproven; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies or clinical trials; Avidity's dependence on third parties in connection with preclinical and clinical testing and product manufacturing; regulatory developments in the United States and foreign countries; and other risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Michael MacLean
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot Rai
(619) 837-5016
media@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-announces-appointment-of-john-b-moriarty-jr-as-chief-legal-officer-302213820.html
SOURCE Avidity Biosciences, Inc.
FAQ
Who is the new Chief Legal Officer of Avidity Biosciences (RNA)?
What is Avidity Biosciences (RNA) focusing on in its clinical development?
What is Avidity Biosciences' (RNA) main technology platform?
What was John B. Moriarty's most recent position before joining Avidity Biosciences (RNA)?
